ATRS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ATRS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Gross Margin % is calculated as gross profit divided by its revenue. Antares Pharma's Gross Profit for the three months ended in Mar. 2022 was $22.8 Mil. Antares Pharma's Revenue for the three months ended in Mar. 2022 was $41.6 Mil. Therefore, Antares Pharma's Gross Margin % for the quarter that ended in Mar. 2022 was 54.84%.
The historical rank and industry rank for Antares Pharma's Gross Margin % or its related term are showing as below:
During the past 13 years, the highest Gross Margin % of Antares Pharma was 62.89%. The lowest was 44.82%. And the median was 57.49%.
Antares Pharma had a gross margin of 54.84% for the quarter that ended in Mar. 2022 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Antares Pharma was 6.80% per year.
The historical data trend for Antares Pharma's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Antares Pharma Annual Data | |||||||||||||||||||||
Trend | Dec12 | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | |||||||||||
Gross Margin % | Get a 7-Day Free Trial | 49.62 | 51.12 | 59.25 | 57.82 | 62.89 |
Antares Pharma Quarterly Data | ||||||||||||||||||||
Jun17 | Sep17 | Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | |
Gross Margin % | Get a 7-Day Free Trial | 60.92 | 63.45 | 65.91 | 61.08 | 54.84 |
For the Medical Instruments & Supplies subindustry, Antares Pharma's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, Antares Pharma's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Antares Pharma's Gross Margin % falls into.
Gross Margin is the percentage of Gross Profit out of sales or Revenue.
Antares Pharma's Gross Margin for the fiscal year that ended in Dec. 2021 is calculated as
Gross Margin % (A: Dec. 2021 ) | = | Gross Profit (A: Dec. 2021 ) | / | Revenue (A: Dec. 2021 ) |
= | 115.7 | / | 183.982 | |
= | (Revenue - Cost of Goods Sold) | / | Revenue | |
= | (183.982 - 68.281) | / | 183.982 | |
= | 62.89 % |
Antares Pharma's Gross Margin for the quarter that ended in Mar. 2022 is calculated as
Gross Margin % (Q: Mar. 2022 ) | = | Gross Profit (Q: Mar. 2022 ) | / | Revenue (Q: Mar. 2022 ) |
= | 22.8 | / | 41.557 | |
= | (Revenue - Cost of Goods Sold) | / | Revenue | |
= | (41.557 - 18.767) | / | 41.557 | |
= | 54.84 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Antares Pharma (NAS:ATRS) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Antares Pharma had a gross margin of 54.84% for the quarter that ended in Mar. 2022 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Thank you for viewing the detailed overview of Antares Pharma's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Karen L. Smith | director | C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2 |
Carmen B Volkart | director | C/O MODULAR MEDICAL, INC., 16772 WEST BERNARDO DRIVE, SAN DIEGO CA 92127 |
Peter C Richardson | officer: See Remarks | 28903 NORTH AVENUE PAINE, VALENCIA CA 91355 |
Fred M Powell | officer: Executive Vice President & CFO | C/O BEJING MED-PHARM CORPORATION 600 W. GERMANTOWN PIKE, SUITE 400 PLYMOUTH MEETING PA 19462 |
Thomas J Garrity | director | |
Roche Robert P Jr | director | 41 MOORES ROAD FRAZER PA 19355 |
Leonard S Jacob | director | C/O INKINE PHARMACEUTICAL COMPANY INC 425 PARK AVENUE NEW YORK NY 10022 |
Peter J Graham | officer: See Remarks | 315 E. 72ND ST., APT 5E, NEW YORK NY 10021 |
Peter Greenleaf | director | ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878 |
Anton Gueth | director | |
Robert F Apple | director, officer: President & CEO | C/O INKLINE PHARMACEUTICAL CO INC SENTRY PARK EAST 1720 WALTON ROAD BLUE BELL PA 19422 |
Marvin Samson | director | |
Jacques Gonella | director | C/O ANTARES PHARMA INC 707 EAGLEVIEW BLVD SUITE 414 EXTON PA 19341 |
James Patrick Tursi | officer: EVP, Chief Medical Officer | 106 ASHLEY COURT, MOORESTOWN NJ 08057 |
Keith E Muckenhirn | officer: VP/Controller & Interim CFO | C/O ANTARES PHARMA, INC. 3905 ANNAPOLIS LANE N, SUITE 105 PLYMOUTH MN 55447 |
From GuruFocus
By GuruFocusNews GuruFocusNews • 04-13-2022
By PRNewswire PRNewswire • 05-19-2022
By Business Wire Business Wire • 04-26-2022
By GuruFocus Research GuruFocus Editor • 08-16-2022
By GuruFocusNews GuruFocusNews • 04-19-2022
By PRNewswire PRNewswire • 06-05-2022
By PRNewswire PRNewswire • 04-13-2022
By PRNewswire PRNewswire • 04-18-2022
By GuruFocus Research GuruFocus Editor • 08-15-2022
By PRNewswire PRNewswire • 04-13-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.